Cheryl Creuzot
About Cheryl D. Creuzot
Independent director of The Bancorp, Inc. since 2021; age 65. She is Chair of the Nominating & Governance Committee and serves on the Audit and Risk Committees (independent under Nasdaq standards). Background includes President Emerita of SEC/FINRA-registered Wealth Development Strategies firms (prior Principal & Managing Partner 2000–2018) and extensive governance roles across financial and public-sector organizations; she earned NACD Directorship Certification in 2025. Board-wide, directors recorded ~98% board attendance and 100% committee attendance for nominees serving in 2024, reflecting strong engagement .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Wealth Development Strategies, LLC & Wealth Development Strategies Investment Advisory, Inc. | President Emerita; previously Principal & Managing Partner | President Emerita since 2018; Principal/Managing Partner 2000–2018 | SEC/FINRA-registered firms; finance, compliance, investment oversight |
| Amegy Bank | Director | Jan 2021 – Oct 2021 | Board service at depository institution |
| Unity National Bank | Director | 2008 – 2015 | Chaired Compliance, Audit, and Investment Committees |
| Port of Houston | Commissioner | 2020 – 2024 | Public-sector governance and oversight |
| Texas Public Finance Authority | Vice Chair (former) | Not disclosed | State-level public finance oversight |
| University of Houston Board of Visitors | Chair (former) | Not disclosed | Higher-education governance |
| Greater Houston Partnership | Board Member (former) | Not disclosed | Regional economic development leadership |
External Roles
| Organization | Type | Role | Tenure | Notes |
|---|---|---|---|---|
| VALIC Company I (Corebridge-affiliated mutual fund complex) | Investment company | Director | Since Oct 2022 | Affiliated with Corebridge Financial, Inc. (NYSE: CRBG) |
| The Frenchy’s Companies | Private company | Director | Not disclosed | Family-owned food manufacturing/restaurant/franchising |
| BeyGood Foundation | Non-profit | Director; Finance & Investment Committees | Since 2022 | Non-profit governance and investment oversight |
| MD Anderson Cancer Center Board of Visitors | Non-profit | Member; President’s Executive Council | Since 2013 | Major academic medical center oversight |
| Other public company boards | — | — | — | None (per proxy) |
Board Governance
- Independence: Determined independent under Nasdaq listing standards; all standing committees are composed exclusively of independent directors .
- Committee assignments: Chair, Nominating & Governance; Member, Audit; Member, Risk .
- Board leadership: Independent Chair separate from CEO; Board and committees hold executive sessions without management .
- Attendance: Board reported ~98% board attendance and 100% committee attendance for nominees serving during 2024; all then-serving directors attended the 2024 annual meeting except one former director .
- 2024 committee workload context (meetings): Audit (6), Compensation & Talent (4), Risk (7), Nominating & Governance (6), ESG (3) .
Fixed Compensation
| Component | Policy/Amount | 2024 Amount for Creuzot | Notes |
|---|---|---|---|
| Annual cash retainer | $75,000 | Included in cash total | Standard for independent directors |
| Committee chair fee | $5,000 (non-Audit chairs) | Included in cash total | Chair of Nominating & Governance |
| Committee member fees | $2,500 per committee; Audit members $5,000 | Included in cash total | Member: Audit (higher member fee), Risk |
| Board Chair premium | $70,000 | N/A | Applies only to non-executive Board Chair |
| Director equity grant (RSUs) | $90,000 grant date market value | $90,000 | Issued at annual meeting; 2024 closing price $32.32 on May 30, 2024 |
| Total cash fees (2024) | — | $86,875 | As reported in Director Compensation Table |
| Total (cash + equity) (2024) | — | $176,875 | As reported |
Performance Compensation
| Element | Structure | Metrics/Terms |
|---|---|---|
| Annual equity grant (RSUs) | $90,000 grant date market value | Granted to each independent director elected at the annual meeting to align interests with stockholders; no specific director performance metrics disclosed |
The proxy does not disclose any performance metrics tied to director compensation (equity is time-based RSUs to align with shareholders). Directors may elect to take some or all cash retainers in stock awards, further aligning incentives .
Other Directorships & Interlocks
| Relationship area | Detail | Governance/Conflict note |
|---|---|---|
| Public company directorships | None (per proxy) | Reduces overboarding risk |
| Investment company boards | VALIC Company I (Corebridge-affiliated) | No related-party transactions with TBBK disclosed involving Mrs. Creuzot |
| Prior bank boards | Amegy Bank; Unity National Bank (committee chair roles) | Banking/compliance expertise; no conflicts disclosed |
| Non-profits/private boards | MD Anderson; BeyGood; Frenchy’s; others | Community and governance breadth |
Expertise & Qualifications
- Finance, audit, investment, and compliance leadership; prior chairing of bank compliance/audit/investment committees; President Emerita of SEC/FINRA-regulated wealth firms .
- NACD Directorship Certification (2025) evidencing continuing governance education .
- Public-sector oversight (Port of Houston; Texas Public Finance Authority) and higher education governance (University of Houston), complementing financial services expertise .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Ownership Guidelines | Compliance | Hedging/Pledging |
|---|---|---|---|---|---|
| Cheryl D. Creuzot | 7,638 | <1% | Directors must own ≥2x annual fees in common stock | All directors and executive officers are in compliance as of proxy date | Hedging and pledging of company stock prohibited by policy |
Notes:
- Beneficial ownership based on 47,954,218 shares outstanding as of April 2, 2025 .
- Insider stock ownership table confirms direct ownership; no pledging disclosed .
Governance Assessment
- Strengths for investor confidence:
- Independent director; chairs Nominating & Governance and sits on Audit and Risk—high-relevance committees for oversight .
- Strong board practices: independent Chair, executive sessions, majority independent board, annual elections, majority voting, robust committee charters and annual self-evaluations .
- Alignment mechanisms: stock ownership guidelines (directors ≥2x annual fees), annual RSU grants, anti-hedging/pledging policy .
- Engagement/attendance: board reported ~98% board attendance and 100% committee attendance for nominees serving in 2024 .
- No related-party transactions disclosed involving Mrs. Creuzot; company’s related-party lending to insiders conforms with Regulation O and did not present unfavorable features as of year-end 2024 .
- Watch items:
- Multiple external roles (investment company board, non-profits) require continued monitoring for time-commitment, though proxy lists no other public company boards and discloses no conflicts .
- Company-wide say-on-pay support remained high (96% in 2024), reducing governance risk signaling around compensation, though this pertains to executive compensation rather than directors .